Given the multifaceted interaction of various mediators in the pathophysiology of PD, and the potential of baicalein to regulate these processes, the current review has been structured to examine the mechanisms by which baicalein can produce its antiparkinsonian effects.
The natural flavonoid Astragalin concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways.
Jun Wang, Jie-Yu He, Qin Huang et al.· Free Radical Biology & Medic...· 0 citations
Overall, postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in PD, although their safety, efficacy, optimal dosing, and clinical utility require further investigations.
Anjali Kumari, K. Aran· Metabolic brain disease· 0 citations
Combined in silico and experimental findings highlight hesperidin’s strong binding to key molecular targets, whereas experimental evidence also confirms its antioxidant, anti-inflammatory, and anti-apoptotic effects, supporting its potential as a disease-modifying candidate in PD therapy.
Seyawash Ghani, Diksha Dalal, Anish Singh et al.· Current Behavioral Neuroscie...· 0 citations
GN is a brain-penetrant preclinical candidate that links ATG16L1-dependent autophagy with α-synuclein clearance and NLRP3 inflammasome suppression in PD models and completely abrogated the neuroprotective and anti-inflammatory effects of GN both in vitro and in vivo.
Cheng-Fu Su, Zhi-Qiang Deng, Ka-Yee Ying et al.· Phytomedicine· 0 citations
